PT  - JOURNAL ARTICLE
ED  - ,
TI  - ▼Jaydess IUS
AID  - 10.1136/dtb.2015.1.0304
DP  - 2015 Jan 01
TA  - Drug and Therapeutics Bulletin
PG  - 9--12
VI  - 53
IP  - 1
4099  - http://dtb.bmj.com/content/53/1/9.short
4100  - http://dtb.bmj.com/content/53/1/9.full
SO  - Drug Ther Bull2015 Jan 01; 53
AB  - In the UK, around 75% of women of reproductive age use some form of contraception.1 Although combined oral contraceptives and barrier contraception are the most widely used, their effectiveness is dependent on their correct and consistent use. In contrast, long-acting reversible contraceptives provide effective and reliable methods of contraception that are not reliant upon user adherence.2 ▼Jaydess (Bayer) is a new long-acting reversible levonorgestrel-releasing intra-uterine delivery system (IUS) that provides contraception for up to 3 years.3 It was launched in April 2014, and is the second levonorgestrel IUS available in the UK. Here we discuss the evidence for its effectiveness and safety, and consider its place in therapy.